165 related articles for article (PubMed ID: 1586707)
21. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
Kreitman RJ
BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
[TBL] [Abstract][Full Text] [Related]
22. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
Foss FM
Clin Lymphoma; 2000 Sep; 1(2):110-6; discussion 117. PubMed ID: 11707818
[TBL] [Abstract][Full Text] [Related]
23. Prolongation of cardiac allograft survival in murine recipients treated with a diphtheria toxin-related interleukin-2 fusion protein.
Kirkman RL; Bacha P; Barrett LV; Forte S; Murphy JR; Strom TB
Transplantation; 1989 Feb; 47(2):327-30. PubMed ID: 2645719
[TBL] [Abstract][Full Text] [Related]
24. Bilateral adrenal hemorrhage and adrenal insufficiency in a patient with lymphomatous adrenal infiltration following administration of a fusion toxin (DAB486 interleukin-2).
Cohen R; Jaffe ES; Stetler-Stevenson MA; Sausville EA; DeNigris EC; Woodworth T; Foss FM
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):229-33. PubMed ID: 7834123
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.
Bachanova V; Frankel AE; Cao Q; Lewis D; Grzywacz B; Verneris MR; Ustun C; Lazaryan A; McClune B; Warlick ED; Kantarjian H; Weisdorf DJ; Miller JS; Vallera DA
Clin Cancer Res; 2015 Mar; 21(6):1267-72. PubMed ID: 25770294
[TBL] [Abstract][Full Text] [Related]
26. Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene.
Shao RH; Tian X; Gorgun G; Urbano AG; Foss FM
Leuk Res; 2002 Dec; 26(12):1077-83. PubMed ID: 12443879
[TBL] [Abstract][Full Text] [Related]
27. DAB486IL-2 (IL-2 toxin) selectively inactivates high-affinity IL-2 receptor-bearing human peripheral blood mononuclear cells.
Waters CA; Snider CE; Itoh K; Poisson L; Strom TB; Murphy JR; Nichols JC
Ann N Y Acad Sci; 1991 Dec; 636():403-5. PubMed ID: 1793228
[No Abstract] [Full Text] [Related]
28. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
[TBL] [Abstract][Full Text] [Related]
29. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders.
Turturro F
Expert Rev Anticancer Ther; 2007 Jan; 7(1):11-7. PubMed ID: 17187516
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules.
Strom TB; Kelley VR; Murphy JR; Nichols J; Woodworth TG
Annu Rev Med; 1993; 44():343-53. PubMed ID: 8476255
[TBL] [Abstract][Full Text] [Related]
31. The role of recombinant interleukin-2 in therapy for hematologic malignancies.
Dutcher JP; Wiernik PH
Semin Oncol; 1993 Dec; 20(6 Suppl 9):33-40. PubMed ID: 8284690
[No Abstract] [Full Text] [Related]
32. Inhibition of human antigen-specific memory B cell response in vitro by a diphtheria toxin-related interleukin 2 fusion protein.
Grailer AP; Nichols JC; Strom TB; Sollinger HW; Burlingham WJ
Cell Immunol; 1991 Feb; 132(2):481-93. PubMed ID: 1988163
[TBL] [Abstract][Full Text] [Related]
33. DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
LeMaistre CF
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S37-40. PubMed ID: 11707862
[TBL] [Abstract][Full Text] [Related]
34. Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats.
Phillips SM; Bhopale MK; Constantinescu CS; Ciric B; Hilliard B; Ventura E; Lavi E; Rostami A
J Neurol Sci; 2007 Dec; 263(1-2):59-69. PubMed ID: 17603081
[TBL] [Abstract][Full Text] [Related]
35. Peripheral blood hairy cell leukemia cells express only low affinity IL-2 receptors.
Bulger K; Murphy J; Janckila A; Nichols J; McCaffrey R
Leuk Res; 1994 Feb; 18(2):101-4. PubMed ID: 8107487
[TBL] [Abstract][Full Text] [Related]
36. Impact of interleukin-2-receptor-targeted cytotoxins on a unique model of murine interleukin-2-receptor-expressing malignancy.
Bacha PA; Forte SE; McCarthy DM; Estis L; Yamada G; Nichols JC
Int J Cancer; 1991 Aug; 49(1):96-101. PubMed ID: 1874577
[TBL] [Abstract][Full Text] [Related]
37. Early clinical studies of IL-2 fusion toxin in patients with severe rheumatoid arthritis and recent onset insulin-dependent diabetes mellitus.
Woodworth TG
Clin Exp Rheumatol; 1993; 11 Suppl 8():S177-80. PubMed ID: 8324945
[TBL] [Abstract][Full Text] [Related]
38. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression.
Morgan SJ; Seymour JF; Prince HM; Westerman DA; Wolf MM
Clin Cancer Res; 2004 May; 10(10):3572-5. PubMed ID: 15161717
[No Abstract] [Full Text] [Related]
39. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
Frankel AE; Fleming DR; Hall PD; Powell BL; Black JH; Leftwich C; Gartenhaus R
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3555-61. PubMed ID: 14506141
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497.
Kuzel TM; Li S; Eklund J; Foss F; Gascoyne R; Abramson N; Schwerkoske JF; Weller E; Horning SJ
Leuk Lymphoma; 2007 Dec; 48(12):2397-402. PubMed ID: 17943599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
